MedTrace Logo

Perioperative Safety of Bladder Hydrodistension in Patients on Antithrombotic Therapy

NCT05221944 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 387

Last updated 2023-09-15

No results posted yet for this study

Summary

After obtaining an institutional ethics approval (#2019186), we retrospectively reviewed patients with interstitial cystitis/bladder pain syndrome (IC/BPS) who underwent hydrodistension in our hospital during January 2010 and May 2021. The diagnosis of IC/BPS was made by the same senior urologist according to the National Institute of Diabetes, Digestive and Kidney Diseases guidelines. Patients who met the inclusion and exclusion criteria were considered eligible for the study. Medical records were reviewed to extract baseline information, including age, body mass index (BMI), duration, antithrombotic use and classification, symptom assessment, and perioperative parameters. Patients were then contacted and volunteered to undergo a follow-up. Telemedicine-based follow-ups were performed at 3 after surgery. Complications and symptoms were recroded. Then, perioperative parameters, including operation time, hospital stays, catheterization time, and hematological results (hemoglobin, platelet count, and coagulated parameters) were recorded based on medical records. The data were analyzed to investigate if perioperative complications were more common in patients with IC/BPS on antithrombotic therapy after bladder hydrodistension.

Conditions

  • Complication

Interventions

OTHER

Patients had a history of antithrombotic therapy

Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.

OTHER

Patients had no history of antithrombotic therapy

Patients had no history of antithrombotic therapy

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Wei-min Li, PhD. · West China Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-04
Primary Completion
2024-02-10
Completion
2024-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221944 on ClinicalTrials.gov